These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 25216867)

  • 1. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
    Ying H; Yang XD; Sun Z; Ning X; Wang Y; Bai C; Chen S; Wang Y
    Med Oncol; 2014 Oct; 31(10):220. PubMed ID: 25216867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
    Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ
    Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
    Sun JM; Won YW; Kim ST; Kim JH; Choi YL; Lee J; Park YH; Ahn JS; Park K; Ahn MJ
    J Cancer Res Clin Oncol; 2011 Apr; 137(4):687-94. PubMed ID: 20552223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
    Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
    Takeda M; Okamoto I; Nakagawa K
    J Thorac Oncol; 2014 Feb; 9(2):200-4. PubMed ID: 24419417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
    Heon S; Yeap BY; Lindeman NI; Joshi VA; Butaney M; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE
    Clin Cancer Res; 2012 Aug; 18(16):4406-14. PubMed ID: 22733536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
    Ono T; Igawa S; Kurahayashi S; Okuma Y; Sugimoto A; Kusuhara S; Ozawa T; Fukui T; Sasaki J; Mitsufuji H; Yokoba M; Kubota M; Katagiri M; Naoki K
    Invest New Drugs; 2020 Jun; 38(3):885-893. PubMed ID: 32157598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M
    Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.
    Wang C; Zhao K; Hu S; Dong W; Gong Y; Li M; Xie C
    Lung Cancer; 2022 Oct; 172():86-93. PubMed ID: 36027855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
    Yeo WL; Riely GJ; Yeap BY; Lau MW; Warner JL; Bodio K; Huberman MS; Kris MG; Tenen DG; Pao W; Kobayashi S; Costa DB
    J Thorac Oncol; 2010 Jul; 5(7):1048-53. PubMed ID: 20512075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.